59edb635f3
- Source: inbox/queue/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
1.6 KiB
Psychopharmacology Institute
Type: Continuing Medical Education (CME) platform
Focus: Psychiatry and mental health prescribing
Significance: De facto clinical guidance infrastructure for US psychiatrists in the absence of formal APA clinical practice guidelines
Overview
The Psychopharmacology Institute is a widely used CME platform for psychiatrists and mental health prescribers in the United States. As of Q1 2026, it functions as the primary channel through which psychiatrists receive structured clinical guidance on emerging psychopharmacology topics, including GLP-1 receptor agonist use in psychiatric populations.
Role in GLP-1 Psychiatric Guidance
In the absence of formal American Psychiatric Association clinical practice guidelines for GLP-1 use, the Institute's quarterly reviews serve as de facto professional guidance. The Q1 2026 review established specific protocols for GLP-1 use in schizophrenia patients on clozapine or olanzapine, including:
- HbA1c screening threshold of 5.4% (below the 5.7% prediabetes cutoff)
- Monthly monitoring using validated depression/suicidality tools
- Psychoeducation protocols for patients and caregivers
- Priority population framing: metabolic side effect management for patients on necessary antipsychotics
The Institute's guidance represents the informal, high-volume competency pathway for psychiatrists, contrasting with the formal ~60-hour ABOM certification pathway.
Timeline
- 2026-04-01 — Published Q1 2026 review covering GLP-1 RAs in psychiatric practice, establishing clinical protocols for schizophrenia patients on metabolically harmful antipsychotics